As a small company, Ultupharma’s business model is to patent new inventions and to out-license, or enter into collaborations at an early stage. The ULT1 (SE539512, US10471043, US10933048), ULT2 (SE540411, US10828316, US10828317, JP6895435, EP/NL/IE/GB/FR/DE/CH/BE3407898, HK40000701, ZL201780004884.X, AU2017212224, CA3007831) and ULT3 (SE543054, US11981755, ZL201980056367.6, JP7492503, AU2019329130, PCT/SE2019/050789) patents are open for out-licensing/collaboration to one or more partners.

A presentation of patented new antibiotics is available on request. This gives details about MIC values, FoR, mechanisms of action, animal studies and clinical possibilities.